The NeoKidney: Next Generation Hemodialysis Device Making Hemodialysis Finally Portablebroad
PORTADIALYS · Horizon Europe grant · 2025-07-01–2027-06-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATOROPEN-01. CORDIS record →
Objective
NextKidney BV, founded in 2014 and based in Netherlands, is revolutionizing kidney care with NeoKidney, a compact, truly portable home hemodialysis (HHD) device. With over 5 million end-stage renal disease (ESRD) patients worldwide, most rely on costly, in-clinic dialysis, which limits mobility, increases fatigue, and has sub-optimal health outcomes. HHD offers benefits over in-clinic dialysis, but adoption remains below 2% due to current devices being bulky and challenging to set up. NeoKidney addresses these barriers by offering a 10 kg portable device that uses patented sorbent technology to recycle dialysate, reducing fluid needs from 45 to 5 liters per session. Its innovative cardiac floating technology also eliminates the need for electrical grounding, enabling use in various settings, including remote and disaster zones. Together, these features make NeoKidney more easily accessible to patients.NeoKidney’s benefits include 40% reduction in mortality, greater patient independence, and healthcare cost savings of up to 43% per patient annually (from €92K to €53K). Integrated remote monitoring allows healthcare providers to track patient data in real time, reducing need for hospital visits. With global dialysis market valued at €82 billion in 2022, and HHD segment expected to grow to €7 billion by 2035, NeoKidney aims to capture significant market share, with projected sales of €650M annually by 2035. NextKidney's commercialization strategy includes selling both the NeoKidney device and high-margin consumables, with initial market entry in Europe and the U.S. NextKidney seeks €41.5M in funding, including €2.5M in EIC grants and €39M in equity (€15M from EICA and €24M from current and additional investors), to accelerate clinical trials, regulatory approval, and market penetration. This funding is critical for maintaining NextKidney’s first-mover advantage, ensuring the rapid rollout of this life-changing technology for home hemodialysis patients.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| NextKidney B.V. | NL | coordinator | €2,499,810 | Yes |
| NextKidney SA | CH | associatedPartner | — |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.